FEMRING
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FEMRING (FEMRING).
Femring (estradiol acetate) is a vaginal ring that releases estradiol, which binds to estrogen receptors (ERα and ERβ) in target tissues, regulating gene transcription and exerting estrogenic effects on the vaginal epithelium, urogenital tract, and other estrogen-sensitive tissues.
| Metabolism | Estradiol acetate is hydrolyzed to estradiol, which is metabolized primarily in the liver via cytochrome P450 (CYP) enzymes, mainly CYP3A4 and CYP1A2, to estrone and estriol; undergoes enterohepatic recirculation. |
| Excretion | Estradiol is primarily excreted in urine (about 90-95%) as conjugated metabolites (glucuronides and sulfates), with approximately 5-10% eliminated in feces via bile. Less than 5% is excreted unchanged. |
| Half-life | The terminal elimination half-life of estradiol from the vaginal ring (Femring) is approximately 36 hours. This extended half-life supports once-monthly dosing and maintains steady-state concentrations. |
| Protein binding | Approximately 97-99% of circulating estradiol is bound to albumin (about 60%) and sex hormone-binding globulin (SHBG, about 38%). Binding is reversible and influences free hormone levels. |
| Volume of Distribution | The apparent volume of distribution for estradiol is approximately 1.2 L/kg, indicating extensive distribution into tissues, including adipose tissue, breast, and reproductive organs. |
| Bioavailability | Femring provides systemic estradiol delivery via vaginal absorption with high bioavailability, estimated to be 50-80% relative to intravenous administration, due to avoidance of first-pass hepatic metabolism. |
| Onset of Action | Systemic estradiol concentrations reach therapeutic levels within 2-4 hours after vaginal ring insertion; clinical effects on vasomotor symptoms (hot flashes) are typically noted within 2-4 weeks of continuous use. |
| Duration of Action | Each ring provides continuous estradiol release for 90 days (3 months), with sustained therapeutic effect on menopausal symptoms throughout the entire wear period. |
| Molecular Weight | 272.38 |
Insert one vaginal ring containing 0.05 mg or 0.10 mg estradiol acetate per day; replace every 3 months.
| Dosage form | INSERT, EXTENDED RELEASE |
| Renal impairment | No dosage adjustment required in renal impairment. |
| Liver impairment | Contraindicated in patients with hepatic impairment; no dosage adjustment guidelines available. |
| Pediatric use | Not indicated for pediatric use; safety and efficacy not established. |
| Geriatric use | Use with caution; lowest effective dose recommended; limited data in women >65 years. |
| 1st trimester | Estradiol vaginal ring is contraindicated in the first trimester due to risk of teratogenicity and potential feminization of male fetus. |
| 2nd trimester | Use only if clearly needed and benefit outweighs risk; may be used for estrogen deficiency symptoms after careful risk-benefit analysis. |
| 3rd trimester | Use only if clearly needed; estrogens can delay labor and cause fetal harm. Consider non-hormonal alternatives. |
Clinical note
Comprehensive clinical and safety monograph for FEMRING (FEMRING).
| Placental transfer | Estradiol crosses the placenta. Fetal concentrations can reach up to 1-5% of maternal levels following vaginal administration; systemic absorption varies. |
| Breastfeeding | Estradiol is excreted in breast milk in low amounts. Use caution, especially with high doses, due to potential for reduced milk production and adverse effects on infant development. American Academy of Pediatrics considers estradiol compatible with breastfeeding. |
■ FDA Black Box Warning
Estrogens increase the risk of endometrial cancer in postmenopausal women with an intact uterus. Use progestin in women with a uterus; Femring is not recommended in women with a uterus. Also, estrogens should not be used to prevent cardiovascular disease or dementia.
| Serious Effects |
Known or suspected pregnancyUndiagnosed abnormal genital bleedingKnown or suspected breast cancerKnown or suspected estrogen-dependent neoplasiaActive or history of venous thromboembolismActive or recent arterial thromboembolic diseaseKnown liver dysfunction or diseaseKnown protein C, protein S, or antithrombin deficiencyKnown hypersensitivity to estradiol or any excipients
| Precautions | Cardiovascular disorders (e.g., stroke, DVT, pulmonary embolism) – increased risk, Malignancy (endometrial, breast, ovarian) – increased risk, Dementia – possible increased risk in women ≥65 years, Gallbladder disease, Hypertriglyceridemia, Fluid retention, Hypocalcemia in hypoparathyroidism, Exacerbation of endometriosis, Hereditary angioedema, Ocular abnormalities (e.g., retinal vascular thrombosis) |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L3 - Probably Compatible |
| Teratogenic Risk | Estradiol is teratogenic. Use during pregnancy is contraindicated. First trimester exposure associated with congenital anomalies including cardiovascular and limb defects. Second and third trimester exposure may cause urogenital abnormalities and feminization of male fetuses. |
| Fetal Monitoring | Not applicable as contraindicated in pregnancy. If accidental exposure occurs, monitor fetal development with ultrasound and follow-up for congenital anomalies. |
| Fertility Effects | Estradiol may inhibit ovulation and impair fertility. Effects are reversible upon discontinuation. |
| No specific food interactions. Grapefruit juice may increase estradiol levels; consider limiting consistent intake. |
| Clinical Pearls | Femring (estradiol acetate vaginal ring) delivers systemic estradiol for menopausal hormone therapy. It is inserted vaginally every 90 days and should not be used for local urogenital symptoms alone. Patients with intact uterus require concomitant progestogen to prevent endometrial hyperplasia. Avoid in women with undiagnosed vaginal bleeding, known/suspected breast cancer, or active thromboembolic disorders. Monitor for signs of VTE or gallbladder disease. |
| Patient Advice | Insert ring high into vagina and replace every 3 months (90 days). If ring is expelled, rinse with lukewarm water and reinsert. · Do not use ring during sexual intercourse; can be removed for up to 2 hours per 90-day period. · Regular mammograms and pelvic exams are recommended. Report any unusual vaginal bleeding, breast lumps, or calf/leg pain. · Smoking increases risk of serious cardiovascular side effects; avoid or reduce smoking. |